Stempoint Capital’s Praxis Precision Medicines PRAX Stock Holding History

Stempoint Capital’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.5M	Sell	37,243 -19,024	-34%	-$6.02M	2.15%	15
2026 Q1	$18.1M	Buy	56,267 +35,200	+167%	+$10.9M	3.47%	6
2025 Q4	$6.21M	Buy	+21,067	New	+$3.92M	1.06%	32
2025 Q3	–	Sell	-32,255	Closed	-$1.36M	–	96
2025 Q2	$1.36M	Buy	+32,255	New	+$1.23M	0.44%	42
2025 Q1	–	Sell	-134,178	Closed	-$10.3M	–	74
2024 Q4	$10.3M	Sell	134,178 -39,856	-23%	-$2.88M	2.58%	13
2024 Q3	$10M	Buy	174,034 +144,775	+495%	+$7.82M	3%	11
2024 Q2	$1.21M	Buy	29,259 +2,366	+9%	+$112K	0.36%	42
2024 Q1	$1.64M	Buy	+26,893	New	+$1.21M	0.43%	41

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Stempoint Capital's PRAX Position: Q2 2026 in Review

Stempoint Capital reduced its Praxis Precision Medicines (PRAX) stake by 34% in Q2 2026, selling an estimated $6.02M and leaving 37,243 shares worth $12.5M. The position accounts for 2.15% of the portfolio, ranked #15.

Stempoint Capital first reported a position in PRAX in Q1 2024 and has held it in 8 quarters since. The position peaked at $18.1M in Q1 2026. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Stempoint Capital held 37,243 shares of Praxis Precision Medicines worth $12.5M as of Q2 2026.
Stempoint Capital sold 19,024 Praxis Precision Medicines shares in Q2 2026, an estimated $6.02M.
Praxis Precision Medicines made up 2.15% of Stempoint Capital's portfolio in Q2 2026, its #15 holding.
Stempoint Capital first reported a position in Praxis Precision Medicines in Q1 2024 and has held it in 8 quarters since.
Stempoint Capital's Praxis Precision Medicines position peaked at $18.1M in Q1 2026.
310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.